ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Biophytis

Biophytis (ALBPS)

0.2957
-0.0103
(-3.37%)
Cerrado 30 Enero 10:30AM

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
0.2957
Postura de Compra
0.2956
Postura de Venta
0.302
Volume Operado de la Acción
24,661
0.292 Rango del Día 0.3035
0.0021 Rango de 52 semanas 1.40
Capitalización de Mercado [m]
Precio Anterior
0.306
Precio de Apertura
0.30
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
93,706
Acciones en circulación
295,702,507
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-5.21
Beneficio por acción (BPA)
-0.06
turnover
-
Beneficio neto
-17.03M

Acerca de Biophytis

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
Sede
Paris, Paris, Fra
Fundado
-
Biophytis is listed in the Biological Pds,ex Diagnstics sector of the Euronext with ticker ALBPS. The last closing price for Biophytis was 0.31 €. Over the last year, Biophytis shares have traded in a share price range of 0.0021 € to 1.40 €.

Biophytis currently has 295,702,507 shares in issue. The market capitalisation of Biophytis is 90.48 € million. Biophytis has a price to earnings ratio (PE ratio) of -5.21.

ALBPS Últimas noticias

Biophytis to Restate Previously Issued Financial Statements

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company...

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patien...

PARIS and CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug...

Biophytis Announces Results of 2019 Annual General Meeting of Shareholders

All resolutions within the competence of the Ordinary General Meeting adoptedSecond notice to reconvene the Extraordinary General Meeting to be held in the coming weeks PARIS and CAMBRIDGE...

Biophytis Enters into a Collaboration with the French Muscular Dystrophy Association (AFM-Telethon)

Provides funding for additional preclinical experiments and for the MYODA preparations for the clinical study in Duchenne muscular dystrophy (DMD) PARIS and CAMBRIDGE, Mass., June 13, 2019...

Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer

PARIS and CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...

Biophytis Announces Publication of its 2018 Annual Report

Files 2018 Annual Report with the AMFProvides first quarter 2019 financial statementsEnters into intellectual property agreement with Stanislas Veillet PARIS and CAMBRIDGE, Mass., May 22, 2019...

Biophytis Files Registration Statement for Proposed Initial Public Offering in the United States

PARIS and CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...

Biophytis Reports Annual 2018 Financial Results and Provides Operational Update

Clinical execution and advancement of our SARA program, including initiation of the SARA-INT Phase 2b clinical trial for sarcopeniaLaunch of our MYODA program for Duchenne muscular dystrophy...

Biophytis Announces Three Oral and One Poster Presentations at the 2019 International Conference on Frailty and Sarcopenia Re...

PARIS, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of novel therapeutics for age-related...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.0058-1.923714759540.30150.31510.2902999670.30105148DE
4-0.1042-26.05651412850.39990.460.251910140.29714219DE
12-0.0542-15.490140040.34990.460.25937060.3027265DE
26-0.2583-46.62454873650.5540.840.25698930.3917179DE
520.29085934.693877550.00491.40.002159350140.00677496DE
156-0.119-28.69544248850.41471.40.002157720320.02598022DE
2600.110759.83783783780.1852.730.002148923680.25632404DE

ALBPS - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Biophytis?
El precio actual de las acciones de Biophytis es 0.2957 €
¿Cuántas acciones de Biophytis están en circulación?
Biophytis tiene 295,702,507 acciones en circulación
¿Cuál es la capitalización de mercado de Biophytis?
La capitalización de mercado de Biophytis es EUR 90.48M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Biophytis?
Biophytis ha negociado en un rango de 0.0021 € a 1.40 € durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Biophytis?
El ratio precio/beneficio de Biophytis es -5.21
¿Cuál es la moneda de reporte de Biophytis?
Biophytis presenta sus resultados financieros en EUR
¿Cuál es el último beneficio anual de Biophytis?
El último beneficio anual de Biophytis es EUR -17.03M
¿Cuál es la dirección registrada de Biophytis?
La dirección registrada de Biophytis es 14 AVENUE DE L’OPERA, PARIS, PARIS, 75001
¿Cuál es la dirección del sitio web de Biophytis?
La dirección del sitio web de Biophytis es www.biophytis.com
¿En qué sector industrial opera Biophytis?
Biophytis opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BIODSBiosynex DS
0.0502 €
(80.58%)
96.34k
ALTROTronic s Microsystems
5.30 €
(35.20%)
5
MLWEYWeya
0.027 €
(35.00%)
99k
VACBSPierre & Vacances
0.0708 €
(24.21%)
46.14k
MCPGrupo Media Capital Sgps Sa
2.00 €
(23.46%)
1,000
MLGEQGentlemen S Equity SA
0.0115 €
(-47.73%)
6.2k
NICBSNicox SA
0.0183 €
(-30.68%)
140
AELISAelis Farma SA
3.76 €
(-21.67%)
33.01k
FPGUnion Tech Info
0.28 €
(-18.60%)
24.47k
ALNEVNeovacs
0.32 €
(-17.40%)
21.49k
ATOAtos SE
0.0022 €
(4.76%)
1.56B
BCPBanco Comercial Portugues SA
0.5052 €
(-0.67%)
50M
ALNRGEnergisme SA
0.0041 €
(-6.82%)
29.28M
KPNKoninklijke KPN NV
3.554 €
(-1.88%)
12.28M
ALCYBCybergun
0.0001 €
(0.00%)
9.42M
955 955 42 segundos hace
Thanks DCBill for sharing that. Excellent analysis by TH. The inside scoop so-to-speak.

And it is baffling to me that someone as financially literate as Zandi would not be aware (or choose not to admit) that FHFA itself told us back in the spring of 2021 how wildly non-economic Fa
BigJuan BigJuan 46 segundos hace
GMPR .0001 getting funding done finally? 👀


"Our team meeting with funders in Palm Beach tmrw to close financing  

Working With Auditor Preparing Our year end Filings.  

No New Share Issuances Since early November  

More High
GMPR
s404n1tn0cc s404n1tn0cc 54 segundos hace
I agree with you that you POR isn't closed . But you seem to imply that we're or may be bought out. At exit.
Which I disagree. We should have sued for the 2 Trillion on our swaps bets cause thats what they were.
Bets of Ten times what your covered for. To just accept 17 Billion for su
LEHNQ
jimr1717 jimr1717 58 segundos hace
And now a day off? The market is open
HMBL
JSmith5 JSmith5 1 minuto hace
Aliens!

Commies!! Dirty rotten Commies!

Nats
FNMA
TightCoil TightCoil 1 minuto hace
As long as we stay above $5,
it's a Great Day
FNMA
haha11 haha11 1 minuto hace
$SPMD.... ...DLY.... HH today.....Nota Ma12 Above Zi =above MA50.. OPINION...


$SPMD .DLY..HH
https://schrts.co/DDUGKAwn
$TNA...DLY ..Nota Ma12 under Zi. =under MA50 OPINION...
https://schrts.co/DkUDrBBK
SPMD TNA
GetSeriousOK GetSeriousOK 1 minuto hace
Then, by your own definition in post #337711, you are: a broke man trying to strike oil with paycheck money. Equally assured is the lack of knowledge of the marketplace also associated with their opinion and feelings getting in the way of critical thinking.
BIEL
toohot toohot 1 minuto hace
Ah yes...yet another BIEL newbie with impending BIEL doom. Thank but no thanks.
'Nuff said!



BUY $BIEL$
BIEL
falkus951 falkus951 1 minuto hace
.
AEXAY
BigJuan BigJuan 2 minutos hace
GMPR .0001 getting funding done finally? 👀

"Our team meeting with funders in Palm Beach tmrw to close financing 

Working With Auditor Preparing Our year end Filings. 

No New Share Issuances Since early November 

More Highlighted Det
GMPR
nowwhat2 nowwhat2 2 minutos hace
I'm afraid I don't find your thinking to be very sound....but of course I wish it all the best.

https://investorshub.advfn.com/uimage/uploads/2025/1/30/ngvxhxrp_!_30_2d_9am.jpg
XRPUSD
vlispxpert vlispxpert 2 minutos hace
JSPR hold em if you got em...no reason to sell down here imo, big boys target is:

RBC Cuts Price Target on Jasper Therapeutics to $48 From $68, Keeps Outperform, Speculative Risk

I'll be happy with $14's target...good luck!
JSPR
Monroe1 Monroe1 2 minutos hace
Nothing great to say about sales as of this past year, but improving.

I sure like the looks of the website though. It is the best of any other ticker I have or have seen.

How does the saying go, " The Emperor Has No Clothes " ?
LQMT
docsetc docsetc 2 minutos hace
Wow,.... "Buy CBDW, since a lot of other AI-related companies will prosper."

Oracle, Google, Microsoft, Massie ERP and Anaylsis applications...... CBDW? 😆😆😆
CBDW
docsetc docsetc 2 minutos hace
Wow,.... "Buy CBDW, since a lot of other AI-related companies will prosper."

Oracle, Google, Microsoft, Massie ERP and Anaylsis applications...... CBDW? 😆😆😆
CBDW
falkus951 falkus951 2 minutos hace
$$$$$ $AEXAY BOTTOM BOUNCER 300x COMING UP!! + LOTS OF POSITIVE NEWS LATELY
https://finance.yahoo.com/quote/AEXAY/news/
https://i.ibb.co/rb9WphY/aexay.jpg
AEXAY
AugustaFriends AugustaFriends 2 minutos hace
$JZXN 1.89 look at weekly chart and 8x34 cross shaping up. Trigger is $2.26 and this could fly, based on TA only... see chart below

https://schrts.co/JunbuHdx
JZXN
JSmith5 JSmith5 3 minutos hace
It's always hang on, there's a reward at some future date

A date for release? You want a date?? I'll give you a date!! July 4, 2026. If its good enough for Ackman, its good enough for you. Independence day!

If its a date, date you want, DC Grannie may be available aft
FNMA
zab zab 3 minutos hace
Trump is just a sad, old man. America will have to endure trump for four years. Trump is about to let go of 2 million government workers. Trump gets caught in his lies, and he never cares, he just moves to a different reporter.

https://www.usnews.com/news/politics/articles/2025-01-30
JSmith5 JSmith5 3 minutos hace
It's always hang on, there's a reward at some future date

A date for release? You want a date?? I'll give you a date!! July 4, 2026. If its good enough for Ackman, its good enough for you. Independence day!

If its a date, date you want, DC Grannie may be available aft
FNMA
BirdsOfFire BirdsOfFire 4 minutos hace
The SEC needs to go after people like Robert Clark, former CEO of KGKG . The SEC should confiscate all those million dollar mansions, luxury cars, overseas bank accounts, four houses in France, etc. I am not accusing RC of crimes but it sure looks that way. The government is not doing enough to
KGKG
BBANBOB BBANBOB 4 minutos hace
LOOOOOOKIN GOOOOOOOOOOD
COOP
ORCA ORCA 4 minutos hace
WTF KNOWS BRO.IT COULD TAKE UP TO 5 YEARS.
BRAV
jimr1717 jimr1717 4 minutos hace
And Bam it gets whacked
CRSM

Su Consulta Reciente

Delayed Upgrade Clock